|
Jun 4
|
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
|
|
Jun 4
|
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
|
|
Jun 4
|
Company News for June 4, 2024
|
|
Jun 4
|
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
|
|
Jun 3
|
Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?
|
|
Jun 3
|
FDA considers updating COVID boosters, Novavax stock reacts
|
|
Jun 3
|
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
|
|
Jun 3
|
Update: RBC Raises Moderna's PT to $160 From $135 Amid RSV Vaccine Approval From US FDA, Keeps Outperform Rating
|
|
Jun 3
|
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
|
|
Jun 3
|
Is Moderna Stock a Buy Now That It's a 2-Product Company?
|
|
Jun 3
|
Moderna Investors Just Got Some Bullish News
|
|
Jun 3
|
FDA approves Moderna’s RSV vaccine mRESVIA
|
|
May 31
|
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
|
|
May 31
|
Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors
|
|
May 31
|
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars
|
|
May 31
|
Moderna Looks for Boost From Newly Approved RSV Shot
|
|
May 31
|
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
|
|
May 31
|
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
|
|
May 31
|
Moderna wins FDA approval for RSV vaccine
|
|
May 14
|
Is This a Setback for Moderna?
|